Summit Therapeutics (SMMT) Reports In-Line Q2 EPS
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q2 EPS of (GBP0.28), in-line with the analyst estimate of (GBP0.28).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SLM (SLM) Misses Q2 EPS by 16c; offers guidance
- United Bancorp (UBCP) Reports Q2 EPS of $0.36
- Utah Medical Products (UTMD) Tops Q2 EPS by 84c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
